Squarepoint
VRDN icon

Squarepoint’s Viridian Therapeutics VRDN Stock Holding History

Squarepoint’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
176,955
+133,046
+303% +$2.14M ﹤0.01% 1945
2026
Q1 		$859K Buy
+43,909
New +$1.3M ﹤0.01% 2911
2025
Q2 		– Sell
-99,372
Closed -$1.34M – 5113
2025
Q1 		$1.34M Buy
99,372
+66,121
+199% +$1.13M ﹤0.01% 2405
2024
Q4 		$637K Sell
33,251
-10,328
-24% -$225K ﹤0.01% 3504
2024
Q3 		$991K Sell
43,579
-99,357
-70% -$1.62M ﹤0.01% 2611
2024
Q2 		$1.86M Buy
142,936
+115,980
+430% +$1.61M ﹤0.01% 2102
2024
Q1 		$472K Buy
+26,956
New +$523K ﹤0.01% 3083
2023
Q4 		– Sell
-10,519
Closed -$161K – 4552
2023
Q3 		$161K Buy
+10,519
New +$201K ﹤0.01% 3475
2023
Q1 		– Sell
-17,207
Closed -$503K – 3863
2022
Q4 		$503K Buy
+17,207
New +$396K ﹤0.01% 2287
2022
Q2 		– Sell
-61,390
Closed -$1.14M – 3418
2022
Q1 		$1.14M Buy
+61,390
New +$1.18M ﹤0.01% 1506
2021
Q2 		– Sell
-11,668
Closed -$195K – 3733
2021
Q1 		$195K Buy
+11,668
New +$218K ﹤0.01% 2708
2020
Q3 		– Sell
-7,942
Closed -$132K – 2867
2020
Q2 		$132K Buy
7,942
+3,458
+77% +$39.3K ﹤0.01% 1950
2020
Q1 		$30K Buy
+4,484
New +$52.2K ﹤0.01% 1760
2018
Q2 		– Sell
-1,227
Closed -$129K – 2078
2018
Q1 		$129K Buy
1,227
+356
+41% +$38.7K ﹤0.01% 1552
2017
Q4 		$136K Buy
+871
New +$111K ﹤0.01% 1894

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Squarepoint's VRDN Position: Q2 2026 in Review

Squarepoint increased its Viridian Therapeutics (VRDN) stake by 303% in Q2 2026, buying an estimated $2.14M and bringing the position to 176,955 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Squarepoint first reported a position in VRDN in Q4 2017 and has held it in 15 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Squarepoint held 176,955 shares of Viridian Therapeutics worth $3.25M as of Q2 2026.
  • Squarepoint bought 133,046 Viridian Therapeutics shares in Q2 2026, an estimated $2.14M.
  • Viridian Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1945 holding.
  • Squarepoint first reported a position in Viridian Therapeutics in Q4 2017 and has held it in 15 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.